{
    "root": "3f4e5db8-5bfb-4b24-8465-9757cbaad2be",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "FENOFIBRATE",
    "value": "20250522",
    "ingredients": [
        {
            "name": "FENOFIBRATE",
            "code": "U202363UOS"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSPOVIDONE, UNSPECIFIED",
            "code": "2S7830E561"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "SOYBEAN LECITHIN",
            "code": "1DI56QDM62"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE"
        }
    ],
    "indications": "Fenofibrate is peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet • To reduce elevated LDL-C, Total-C, TG and      Apo B, and to increase HDL- C in adult patients with primary      hypercholesterolemia or mixed dyslipidemia ( 1.1 ). • For treatment of adult patients with      severe hypertriglyceridemia ( 1.2 ). Limitations of Use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus ( 5.1 ).",
    "contraindications": "• Primary hypercholesterolemia or mixed      dyslipidemia: Initial dose of 160 mg once daily ( 2.2 ). • Severe hypertriglyceridemia: Initial dose      of 54 to 160 mg once daily. Maximum dose is 160 mg ( 2.3 ). • Renally impaired patients: Initial dose      of 54 mg once daily ( 2.4 ). • Geriatric patients: Select the dose on      the basis of renal function ( 2.5 ) • Should be given with meals ( 2.1 ).",
    "warningsAndPrecautions": "Fenofibrate tablets, USP are available in two strengths:\n                  160 mg white to off white, oval shaped, film coated tablets debossed with \"LS\" on one side and \"215\" on the other side \n                  Cartons of 30 film coated tablets (10 film coated tablets each blister pack x 3), NDC 0904-7539-04\n                  WARNING: This Unit Dose package is not child resistant and is Intended for Institutional Use Only. Keep this and all drugs out of the reach of children.\n                  \n                     Storage\n                  \n                  Store at 20°C to 25°C [68°F to 77°F] [See USP Controlled Room Temperature]. Keep out of the reach of children. Protect from moisture.",
    "adverseReactions": "Fenofibrate tablet is contraindicated in: \n                  \n                     \n                        •patients with severe renal impairment, including those receiving dialysis [see Clinical Pharmacology (12.3)] .\n                     \n                        •patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities [see Warnings and Precautions (5.2)]\n                     \n                     \n                        •patients with preexisting gallbladder disease [see Warnings and Precautions (5.5)] .\n                     \n                        •nursing mothers [see Use in Specific Populations (8.2)]\n                     \n                     \n                        •patients with known hypersensitivity to fenofibrate or fenofibric acid [see Warnings and Precautions (5.9)]."
}